Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ( ...

Core Insights - Zimmer Biomet (ZBH) is expected to report quarterly earnings of $2.30 per share, reflecting a 4.6% increase year-over-year [1] - Revenue forecasts stand at $2.01 billion, indicating a 3.7% year-over-year growth [1] Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3] Revenue Breakdown - 'Net Sales- Knees' is estimated at $839.93 million, a 5.2% increase from the prior year [5] - 'Net Sales- Other' is projected at $174.21 million, reflecting a 5.2% decrease year-over-year [5] - 'Net Sales- S.E.T' is expected to reach $475.72 million, indicating a 5% increase [5] Regional Sales Estimates - 'Net Sales- Hips' is forecasted at $525.56 million, a 4.1% increase from the previous year [6] - 'Net Sales- Knees- International' is estimated at $347.47 million, showing a 6.3% increase [6] - 'Net Sales- Hips- International' is projected at $252.20 million, reflecting a 4.4% increase [7] U.S. vs. International Sales - 'Net Sales- United States' is expected to reach $1.19 billion, a 5.3% increase year-over-year [8] - 'Net Sales- International' is forecasted at $836.84 million, indicating a 3.1% increase [8] Stock Performance - Over the past month, Zimmer shares have returned +4.4%, outperforming the Zacks S&P 500 composite's +1% [9] - Zimmer currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [9]

Core Viewpoint - Zimmer Biomet Holdings, Inc. is expected to report strong growth in its fourth-quarter 2024 results, driven by performance across its business segments, with revenue and earnings estimates showing positive year-over-year changes [4][3]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $2.01 billion, indicating a 3.7% increase from the previous year [3]. - The Zacks Consensus Estimate for earnings is $2.30 per share, reflecting a 4.6% improvement from the year-ago figure [3]. - The earnings estimates have remained steady over the past 90 days [3]. Business Segment Performance - The Hips business is anticipated to show growth due to the company's comprehensive solutions, including the new Z1 triple-taper hip system and the automated HAMMR surgical impactor [5]. - The total Knee business is expected to report a 3.5% year-over-year growth, benefiting from the traction of the cementless Persona OsseoTi and recent FDA approvals [6][8]. - The S.E.T business is projected to achieve a 7.3% year-over-year growth, supported by the FDA approval of the OsseoFit Stemless Shoulder System [9]. Market Position and Challenges - Zimmer Biomet has faced supply challenges in the Knee segment, which are expected to be resolved in the latter half of 2024 [7]. - The company has completed the acquisition of OrthoGrid, enhancing its product portfolio in the hips category [5]. Earnings ESP and Zacks Rank - Zimmer Biomet has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 4 (Sell), indicating a lower chance of beating earnings estimates [11].

Core Viewpoint - Zimmer Biomet's strategic product launches and market share gains in reconstructive knees and hips are encouraging, although macroeconomic uncertainties are impacting profitability [1] Factors Driving ZBH's Share Price - Zimmer Biomet has achieved strong market share gains in reconstructive knees and hips, with revenues growing by mid-single digits for 11 consecutive quarters [2] - The international business exceeded sales expectations in Q3 2024, driven by strong demand in key markets [2] - The knee business grew 10% internationally despite challenges from ERP system implementation, and the Oxford Partial cementless Knee launch in 2025 is expected to capture 60% of the European market [3] - Upcoming launches in the hip category, including Z1 HAMMR and navigation technologies, are anticipated to enhance market share [3] - The S.E.T. (Surgical, Sports, Upper Extremities, and Restorative Therapies) business has seen mid-single digit sales growth, with expectations for continued growth in 2025 and 2026 [4] - Strategic investments in developed and emerging markets are yielding positive results, particularly in Asia Pacific, contributing to revenue growth [5][6] Factors Hindering ZBH's Growth - Industry-wide staffing shortages and supply chain issues are negatively affecting growth [7] - Geopolitical complications and high interest rates are impacting raw material and labor costs, particularly in the dental treatment space [7] - The S.E.T. category faces reimbursement challenges, especially in Restorative Therapies, along with acute supply challenges in Sports and Trauma [8] - In Q3, the company experienced a 3.9% increase in cost of products sold and a 3.1% rise in selling, general, and administrative expenses, leading to a contraction in adjusted gross and operating margins [9] - Foreign exchange fluctuations have adversely impacted net sales, with an expected 75 basis point negative effect on revenues for the full year [10]

WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be available for replay following the conference call. Individuals ...

Company Overview - Zimmer Biomet Holdings Inc (NYSE: ZBH) is a prominent player in the Health Care Equipment Industry [1] - The company is strategically expanding its product portfolio, which could potentially alter its revenue growth trajectory [1] - Zimmer Biomet remains liquid and is well-positioned to execute its strategic initiatives [1] Industry Context - The Health Care Equipment Industry is a dynamic sector with significant growth potential [1] - Companies in this industry are focusing on product portfolio expansion to drive revenue growth [1] Strategic Initiatives - Zimmer Biomet is actively working on expanding its product offerings, which is a key strategy to enhance its market position [1] - The company's liquidity position supports its ability to invest in strategic growth initiatives [1]

Core Viewpoint - Zimmer Biomet is experiencing growth driven by strategic product launches and market expansion, particularly in emerging markets, despite facing macroeconomic challenges and operational pressures [2][8][9]. Group 1: Revenue Growth and Market Expansion - Strong revenue growth in emerging markets, particularly in the Asia Pacific region, is a key driver for Zimmer Biomet [2]. - The company is on a diversification journey with its S.E.T. business, expecting mid-single-digit sales growth to continue into 2025 and 2026 [3]. - Zimmer Biomet's international business exceeded sales expectations in the third quarter, supported by strong demand in reconstructive knees, hips, and S.E.T. categories [18]. Group 2: Product Launches and Market Share - The company anticipates significant market share gains from upcoming product launches, including the Oxford Partial cementless Knee and Z1 HAMMR in Europe [10]. - Zimmer Biomet has been witnessing strong market share gains in reconstructive knees and hips across key geographies [18]. Group 3: Financial Performance and Challenges - In the third quarter of 2024, Zimmer Biomet's net sales were negatively impacted by foreign exchange rates, with an expected adverse impact of 75 basis points for the full year [15]. - The company faced a 3.9% increase in the cost of products sold and a 3.1% rise in selling, general, and administrative expenses, leading to a contraction in adjusted gross and operating margins [12]. - Staffing shortages, supply chain issues, and geopolitical complications are creating significant pressure on revenues and operating profit [17].

Company Overview - Zimmer Biomet is a global leader in medical technology with a focus on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [1][4] - The company operates in over 25 countries and has sales in more than 100 countries, showcasing its extensive global reach [2] Upcoming Events - Zimmer Biomet management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET) [3] - A live webcast of the presentation will be available on the company's Investor Relations website, with an archived replay following the conference [3]

WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a com ...

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration ("FDA") 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. The system is designed to match the natural humeral (upper shoulder bone) anatomy to optimize anatomical fit while maximizing the preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio. The company plans to launch the system commercially in the first quarter of ...